KPE® - Certificate Program (1 Month)

Recent Articles

• DCGI approved Itolizumab to treat COVID-19 patients with moderate to severe acute respiratory distress 
• Aurobindo Pharma hives off its biosimilars business to subsidiary CuraTeQ Biologics
• Lupin, Mylan receive EUmarketing authorization for Nepexto
• AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer
• Roche’s Elecsys IL-6 test received USFDA EUA
• Gilead’s Voluntary Licensing Agreements for Remdesivir with 5 generic companies
• Market Exclusivity Case Study: XIFAXAN (rifaximin)
• FDA Grants Accelerated Approval to Capmatinib for NSCLC
• Aleor Dermaceuticals receives EIR from US FDA for Karakhadi formulation facility
• Lupin introduces ‘Jan Kovid’ helpline for Mumbai citizens
• Bausch + Lomb – Stada Arzneimittel – Xbrane Biopharma – licensing deal for Lucentis biosimilar
• Valneva And Pfizer to Co-Develop and Commercialize Lyme Disease Vaccine, Vla15
• Ipsen agreement with IRICoR & Université de Montréal to acquire exclusive license for discovery-stage oncology programme
• Global Licensing Agreement Case study: ProThera Biologics and Takeda to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)
• Glenmark Foundation rolls out tele-health solution to expand access to quality patient care
• Florio GmbH introducing new digital platform aiming to improve the lives of people with haemophilia
• Gilead Sciences, Second Genome ink collaboration strategic deal in biomarker and inflammatory bowel disease drug discovery
• Who determines when a prescription medicine should be switched to OTC status?
• What is the difference between purity and potency?
• Case Study: US FDA approves erythroid maturation agent, Reblozyl